Molecular Templates (Molecular Templates) Free Cash Flow : $-42.02 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

Molecular Templates Free Cash Flow Definition

Molecular Templates's total free cash flow for the months ended in Dec. 2023 was $-5.29 Mil. Its total free cash flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-42.02 Mil.

Molecular Templates's Free Cash Flow per Share for the months ended in Dec. 2023 was $-0.98. Its free cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.23.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 31.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Free Cash Flow Growth Rate using Free Cash Flow per Share data.

During the past 13 years, Molecular Templates's highest 3-Year average Free Cash Flow per Share Growth Rate was 60.80% per year. The lowest was -138.10% per year. And the median was 33.00% per year.

Molecular Templates Free Cash Flow Historical Data

The historical data trend for Molecular Templates's Free Cash Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Templates Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Free Cash Flow

Get a 7-Day Free Trial

-34.89

-91.19

-34.38

-92.22

-42.02

Molecular Templates Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Free Cash Flow	Get a 7-Day Free Trial															-18.74	-19.54	-9.66	-7.53	-5.29

Molecular Templates Free Cash Flow Calculation

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Molecular Templates's Free Cash Flow for the fiscal year that ended in Dec. 2023 is calculated as

Free Cash Flow (A: Dec. 2023 )	=	Cash Flow from Operations	+	Capital Expenditure
	=	-41.82	+	-0.2
	=	-42.02

Molecular Templates's Free Cash Flow for the quarter that ended in Dec. 2023 is calculated as

Free Cash Flow (Q: Dec. 2023 )	=	Cash Flow from Operations	+	Capital Expenditure
	=	-5.287	+	0
	=	-5.29

Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.02 Mil.

Molecular Templates (NAS:MTEM) Free Cash Flow Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.

Therefore, as of Dec23, Molecular Templates's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Dec23)	=	Normalized Free Cash Flow	/	Price	+	5-Year EBITDA Growth Rate
	=	0	/	3.73	+	0
	=	0.00 %

Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.

Molecular Templates Free Cash Flow Related Terms

Thank you for viewing the detailed overview of Molecular Templates's Free Cash Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Templates (Molecular Templates) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Templates Inc (NAS:MTEM) » Definitions » Free Cash Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

9301 Amberglen Boulevard, Suite 100, Austin, TX, USA, 78729

Website

https://www.mtem.com

Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer.

Executives

Maurizio Voi	officer: Chief Medical Officer	4 MAGUIRE ROAD, LEXINGTON MA 02421
Biotech Target N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Sean Mclennan	officer: CFO & Treasurer	C/O MOLECULAR TEMPLATES, INC., 93010 AMBERGLEN BLVD., SUITE 100, AUSTIN TX 78729
Kevin M. Lalande	director, 10 percent owner	201 WEST 5TH STREET, AUSTIN TX 78701
Shv Management Services, Llc	10 percent owner	FROST TOWER, 401 CONGRESS AVENUE, SUITE 2950, AUSTIN TX 78701
Gabriela Gruia	director	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Jason S. Kim	officer: See Remarks	9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
Biotech Ag Bb	10 percent owner	SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Sanders Corazon (corsee) D.	director	C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Patrick G Enright	10 percent owner	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Bakker Juliet Tammenoms	10 percent owner	LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
David Hirsch	director, 10 percent owner	C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Longitude Venture Partners Iii, L.p.	10 percent owner	800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Scott D Morenstein	director	C/O CAXTON ALTERNATIVE MANAGEMENT LP, 1330 SIXTH AVENUE, 20TH FLOOR, NEW YORK NY 10019